Apical hypertrophic cardiomyopathy: Present status

M Fuad Jan1, Maria Chiara Todaro2, Lilia Oreto2

  • 1Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, 2801 W. Kinnickinnic River Parkway, Ste. 840, Milwaukee, WI 53215, USA.

Insights

Apical hypertrophic cardiomyopathy (AHC) has diverse global data on its natural history. This review summarizes AHC incidence, features, and prognosis, highlighting its potential impact on sudden cardiac death.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Genetics

Background:

  • Apical hypertrophic cardiomyopathy (AHC) was first described 40 years ago in Japan.
  • Subsequent global research has revealed contrasting information regarding its natural history.
  • AHC is recognized as a heterogeneous clinical entity.

Purpose of the Study:

  • To provide a comprehensive overview of apical hypertrophic cardiomyopathy.
  • To synthesize current knowledge on AHC's incidence, phenotypic expressions, clinical features, prognosis, and management.
  • To assess the potential role of AHC in the burden of sudden cardiac death.

Main Methods:

  • Systematic literature review.
  • Synthesis of data from global studies on AHC.
  • Analysis of reported incidence, clinical presentations, and outcomes.

Main Results:

  • AHC exhibits significant heterogeneity in its presentation and progression worldwide.
  • Data on incidence and prevalence vary across different populations.
  • Clinical features range from asymptomatic to severe manifestations.
  • Prognostic factors and management strategies are still being defined.
  • AHC may contribute more significantly to sudden cardiac death than previously understood.

Conclusions:

  • Apical hypertrophic cardiomyopathy represents a complex cardiovascular condition with a varied natural history.
  • Further research is needed to fully elucidate AHC's epidemiology and long-term outcomes.
  • Recognizing AHC's potential contribution to sudden cardiac death is crucial for clinical practice and patient management.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
618
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
750
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
731
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
548